Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

AbbVie, Shire Agree on Roughly $55B Combination

By Drug Discovery Trends Editor | July 18, 2014

The drugmaker AbbVie has reached a deal worth roughly $55 billion to combine with British counterpart Shire and become the latest U.S. company to seek an overseas haven from corporate income tax rates back home.
 
The companies said Friday that Shire shareholders will receive cash and stock valued at about 53.19 pounds ($91.07) for each of their shares. They will control about 25% of a new company created as part of the deal. AbbVie shareholders will hold the remaining 75%.
 
That new company will be incorporated on the British island of Jersey, where Shire currently is headquartered.
 
U.S.-based multi-national companies looking to grow through acquisitions have been searching more fervently in recent years for these overseas combinations known as inversions. But the deals are drawing growing concern from President Barack Obama and members of Congress because they can cost the United States billions of dollars in tax revenue.
 
At 35%, the United States has the highest corporate income tax rate in the industrialized world, and it also taxes income earned overseas and then brought home. That causes some companies to park millions of dollars in overseas accounts.
 
AbbVie said Friday it expects a tax rate of about 13% by 2016 for the new company created in the deal. A statement from the drugmakers also said the deal gives the resulting company “flexible access to its global cash flows.”
 
AbbVie has said the new tax rate would represent a drop from its current rate of roughly 22%.
 
Inversions can take place if shareholders of the foreign entity involved retain more than a 20% ownership in the newly merged business. Legally, the foreign company might acquire the U.S. business or the two create a new entity. But the U.S. company often maintains both its corporate headquarters and control of the company.
 
This overseas move has grown more common among health care companies. Last month, U.S. medical device maker Medtronic Inc. said that it had agreed to buy Ireland-based competitor Covidien for $42.9 billion in cash and stock. The combined company would have executive offices in Ireland, which has a 12.5% corporate income tax rate.
 
The largest drugstore chain in the United States, Walgreen Co., also is considering a similar move with Swiss health and beauty retailer Alliance Boots. Walgreen bought a 45% stake in Alliance Boots a few years ago and has an option to buy the rest of the company.
 
AbbVie, which makes the blockbuster anti-inflammatory drug Humira, had made several unsolicited takeover bids for Shire before the two companies started talking about a possible deal earlier this month. Shire makes the attention deficit hyperactivity disorder medication Vyvanse as well as rare disease and gastrointestinal treatments.
 
Shire said Friday its board recommends that shareholders vote for the latest offer, and the deal will create “a well-positioned and focused specialty biopharmaceutical company.”
 
U.S.-traded shares of Shire PLC fell $2.84 to $250.60 before markets opened Friday and after the deal was announced. Shares of North Chicago, Illinois-based AbbVie Inc. slipped 77 cents to $52.75.
 
Date: July 18, 2014
Source: Associated Press

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50